{"id":143895,"date":"2026-11-06T20:35:51","date_gmt":"2026-11-06T11:35:51","guid":{"rendered":"https:\/\/japanir.jp\/en\/ir\/4564-20261106-01_wp_financial_summary\/"},"modified":"2026-11-06T20:35:51","modified_gmt":"2026-11-06T11:35:51","slug":"4564-20261106-01_wp_financial_summary","status":"publish","type":"ir_release","link":"https:\/\/japanir.jp\/en\/company\/company-4564\/ir\/4564-20261106-01_wp_financial_summary\/","title":{"rendered":"Financial Summary for the Second Quarter of Fiscal Year Ending March 2027 (Interim) [Japanese GAAP] (Consolidated)"},"content":{"rendered":"<p>Revenue of 335 million yen, a decrease year-over-year. Interim operating loss was 568 million yen, ordinary loss was 572 million yen, and interim net loss attributable to owners of parent was 574 million yen. No earnings forecast for the fiscal year ending March 2027 is provided. Research and development investment continues, with increased costs in the cancer precision medicine-related business. Cash and deposits were 2,083 million yen, and equity experienced changes. New partnerships and clinical development continue.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4564","jir_company_name":"OncoTherapy Science, Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-06","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4564-20261106-01.pdf","jir_short_summary":"Revenue of 335 million yen, a decrease year-over-year. Interim operating loss was 568 million yen, ordinary loss was 572 million yen, and interim net loss attributable to owners of parent was 574 million yen. No earnings forecast for the fiscal year ending March 2027 is provided. Research and development investment continues, with increased costs in the cancer precision medicine-related business. Cash and deposits were 2,083 million yen, and equity experienced changes. New partnerships and clinical development continue.","jir_summary":"### Overview of Business Results\nConsolidated revenues for the interim period were 335 million yen, a decrease compared with the same period of the previous year. The primary causes were expense recognition for basic research and drug discovery research on pharmaceutical candidate compounds and increased cost of sales in the cancer precision medicine-related business, resulting in an operating loss of 568 million yen, an ordinary loss of 572 million yen, and an interim net loss attributable to owners of parent of 574 million yen. By segment, research and development related to pharmaceuticals recorded significant operating losses, and the cancer precision medicine-related business also posted losses. No earnings forecast for the fiscal year ending March 2027 is provided at this time.\n\n### Financial Position and Cash Flows\nAt the end of the interim period, total assets amounted to 2,338 million yen and net assets amounted to 2,062 million yen. Cash and deposits increased to 2,083 million yen. Shareholders' equity increased due to increases of 248 million yen in capital stock and 248 million yen in capital surplus, while retained earnings decreased by 574 million yen. Cash flows from operating activities continued to be negative, while cash flows from financing activities increased by 463 million yen due to funds raised through share issuance.","jir_financial_highlights":"Revenue: 335 million yen (Year-over-Year -96 million yen)\nOperating Income: -568 million yen (YoY Unknown (Prior period -475 million yen))\nOrdinary Income: -572 million yen (Year-over-Year Unknown)\nInterim Net Loss Attributable to Owners of Parent: -574 million yen (Year-over-Year -555 million yen)\nTotal Assets: 2,338 million yen (From End of Previous Fiscal Year -20 million yen)\nNet Assets: 2,062 million yen (From End of Previous Fiscal Year -79 million yen)","jir_category":"","jir_hashtags":"#OncoTherapyScience, #Earnings, #Interim, #RAndDInvestment, #CancerPrecisionMedicine","jir_key_figures":"Revenue: 335 million yen (Year-over-Year -96 million yen)\nOperating Loss: -568 million yen\nOrdinary Loss: -572 million yen\nInterim Net Loss Attributable to Owners of Parent: -574 million yen\nCash and Deposits: 2,083 million yen","jir_meta_title":"OncoTherapy Science, Inc. \u2014 Financial Summary for Q2 FY2027: Interim Results and Financial Position","jir_meta_description":"Summary of OncoTherapy Science, Inc.'s financial summary for the second quarter of FY2027: revenue 335 million yen, operating loss 568 million yen, earnings forecast TBD. Overview of R&D impact and financial position.","jir_og_title":"OncoTherapy Science, Inc. Second Quarter Financial Summary","jir_og_description":"OncoTherapy Science, Inc.'s interim results show revenue of 335 million yen and widening losses. Earnings forecast remains TBD. Highlights the impact of R&D investment and developments in cancer precision medicine.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59269,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-143895","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Financial Summary for the Second Quarter of Fiscal Year Ending March 2027 (Interim) [Japanese GAAP] (Consolidated) - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4564\/ir\/4564-20261106-01_wp_financial_summary\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4564\/ir\/4564-20261106-01_wp_financial_summary\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4564\/ir\/4564-20261106-01_wp_financial_summary\/\",\"name\":\"Financial Summary for the Second Quarter of Fiscal Year Ending March 2027 (Interim) [Japanese GAAP] (Consolidated) - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2026-11-06T11:35:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4564\/ir\/4564-20261106-01_wp_financial_summary\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4564\/ir\/4564-20261106-01_wp_financial_summary\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4564\/ir\/4564-20261106-01_wp_financial_summary\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Financial Summary for the Second Quarter of Fiscal Year Ending March 2027 (Interim) [Japanese GAAP] (Consolidated)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Financial Summary for the Second Quarter of Fiscal Year Ending March 2027 (Interim) [Japanese GAAP] (Consolidated) - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4564\/ir\/4564-20261106-01_wp_financial_summary\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4564\/ir\/4564-20261106-01_wp_financial_summary\/","url":"https:\/\/japanir.jp\/en\/company\/company-4564\/ir\/4564-20261106-01_wp_financial_summary\/","name":"Financial Summary for the Second Quarter of Fiscal Year Ending March 2027 (Interim) [Japanese GAAP] (Consolidated) - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2026-11-06T11:35:51+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4564\/ir\/4564-20261106-01_wp_financial_summary\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4564\/ir\/4564-20261106-01_wp_financial_summary\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4564\/ir\/4564-20261106-01_wp_financial_summary\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"Financial Summary for the Second Quarter of Fiscal Year Ending March 2027 (Interim) [Japanese GAAP] (Consolidated)"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"related_company_data":{"id":"59269","title":"ONCOTHERAPY SCIENCE INC","ticker":"4564"},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/143895","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/ir_release"}],"replies":[{"embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/comments?post=143895"}],"version-history":[{"count":0,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/143895\/revisions"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=143895"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=143895"},{"taxonomy":"importance","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/importance?post=143895"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}